- Home
- SORA vs ARMP Comparison
SORA vs ARMP Comparison
Compare SORA & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SORA | ARMP |
|---|---|---|
| Founded | 2001 | N/A |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.0M | 125.7M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | SORA | ARMP |
|---|---|---|
| Price | $2.61 | $6.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 15.2K | ★ 49.3K |
| Earning Date | 05-12-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,081,504.00 | $5,054,000.00 |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.80 | $0.90 |
| 52 Week High | $14.15 | $16.34 |
Technical Indicators
Market Signals| Indicator | SORA | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 47.38 |
| Support Level | N/A | $5.74 |
| Resistance Level | N/A | $6.37 |
| Average True Range (ATR) | 0.00 | 0.74 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 0.00 | 14.85 |
Price Performance
Historical ComparisonAbout SORA Top Win International Limited Ordinary Shares
AsiaStrategy is a wholesaler engaged in trading, distribution, and retail of luxury watches of international brands. The Group sources its luxury watches from Europe, Singapore, Japan, and Hong Kong, then sells the goods to retail sellers and other distributors in the watch industry.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.